Your session is about to expire
← Back to Search
Sildenafil for Scleroderma (SEPVADIS Trial)
SEPVADIS Trial Summary
This trial is testing whether sildenafil is an effective treatment for Scleroderma with mildly elevated pulmonary pressures.
SEPVADIS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSEPVADIS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 6 Patients • NCT01642407SEPVADIS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My lung function tests show I have more than half the normal breathing capacity.My kidney function is impaired with high creatinine levels.I am unable to carry out any physical activity without discomfort.My scans show no signs of chronic blood clots.I have a heart condition affecting the left side or my heart's pumping ability is reduced.I can walk for six minutes without difficulty.You have been diagnosed with systemic sclerosis using specific criteria set by rheumatology organizations in 2013.I am under 18 years old.Your blood pressure is lower than 90 mmHg when checked before joining the study.I am currently in the hospital or very sick.I have untreated sleep apnea that affects my daily life.I haven't taken any PAH medication in the last 3 months.I am currently using nitrates for my condition.My heart's lung artery pressure was between 21-24 mm Hg, with normal heart pressure, in the last 6 months.
- Group 1: Sildenafil
- Group 2: Placebo
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional research has been conducted on the efficacy of Sildenafil?
"Virginia Commonwealth University/Massey Cancer Center first took up the investigation of sildenafil in 2013, and have since conducted a total of 18456 trials. As for current studies, 23 are still live with many being carried out from New Orleans, Louisiana."
Does this research project still have space for volunteer participants?
"According to the information on clinicaltrials.gov, this research is still accepting participants. It was initially shared on September 20th 2021 and has since been modified as recent as September 8th 2022."
How extensive is the sample size of this research project?
"Affirmative. According to the clinicaltrials.gov repository, this research project is actively recruiting participants since its first post on September 20th 2021. The total number of patients needed across 2 sites amounts to 30 individuals."
In what medical contexts is Sildenafil usually prescribed?
"Sildenafil can be used to combat conditions such as premature ejaculation, NYHA functional class II-III pulmonary arterial hypertension, and general pulmonary arterial hypertension."
Do Sildenafil treatments pose any potential safety risks for patients?
"Although Sildenafil is still being tested, the safety of this medication has been established and thus receives a score of 2."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger